Lipitor Korean Atorvastatin Goal Achievement Across Risk Levels Study
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the percentage of Korean dyslipidemic subjects in the total group and each
cardiovascular risk group achieving LDL-C target as defined by NCEP ATP Ⅲ criteria at
starting doses of 10mg, 20mg and 40mg of atorvastatin after 8 weeks of treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.